Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales). The Group has more than 4,500 employees.
Company Growth (employees)
Boulogne Billancourt, FR
Size (employees)
4,907 (est)+6%
Ipsen was founded in 1929 and is headquartered in Boulogne-Billancourt, FR

Ipsen Office Locations

Ipsen has an office in Boulogne-Billancourt
Boulogne-Billancourt, FR (HQ)
65 Quai Georges Gorse

Ipsen Data and Metrics

Ipsen Financial Metrics


Market capitalization (24-Jul-2017)

9.1 b

Closing share price (24-Jul-2017)

Ipsen's current market capitalization is €9.1 b.

Ipsen Market Value History

Traffic Overview of Ipsen

Ipsen Online and Social Media Presence

Ipsen News and Updates

Ipsen, Hixon get Olympic 3-meter spots, Dumais finishes 4th

INDIANAPOLIS (AP) — With one long hug and a few brief words, Troy Dumais asked Kristian Ipsen to carry on the legacy of American diving.Ipsen smiled, Dumais choked back tears and now the two longtime synchro partners are heading in drastically different directions.On Saturda…

Ipsen Company Life and Culture

You may also be interested in